Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Supratotal Resection of Glioblastoma: Is Less More?

Altieri R, Melcarne A, Soffietti R, Rudá R, Franchino F, Pellerino A, La Rocca G, Sabatino G, Olivi A, Ducati A, Zeppa P, Tardivo V, Mantovani C, Chiovatero I, Martini S, Dolce P, Savastano R, Lanotte MM, Zenga F, Garbossa D.

Surg Technol Int. 2019 Aug 1;35. pii: sti35/1167. [Epub ahead of print]

PMID:
31373379
2.

The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?

Li YM, Suki D, Hess K, Sawaya R.

J Neurosurg. 2016 Apr;124(4):977-88. doi: 10.3171/2015.5.JNS142087. Epub 2015 Oct 23.

PMID:
26495941
3.

Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region.

Jiang H, Cui Y, Liu X, Ren X, Li M, Lin S.

J Neurosurg. 2019 Mar 22:1-8. doi: 10.3171/2018.12.JNS182775. [Epub ahead of print]

PMID:
30901758
4.

The assessment of prognostic factors in surgical treatment of low-grade gliomas: a prospective study.

Majchrzak K, Kaspera W, Bobek-Billewicz B, Hebda A, Stasik-Pres G, Majchrzak H, Ładziński P.

Clin Neurol Neurosurg. 2012 Oct;114(8):1135-44. doi: 10.1016/j.clineuro.2012.02.054. Epub 2012 Mar 17.

PMID:
22425370
5.

Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.

Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA.

J Neurosurg. 2014 Nov;121(5):1115-23. doi: 10.3171/2014.7.JNS132449. Epub 2014 Sep 5.

PMID:
25192475
6.

Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.

Coburger J, Hagel V, Wirtz CR, König R.

PLoS One. 2015 Jun 26;10(6):e0131872. doi: 10.1371/journal.pone.0131872. eCollection 2015.

7.

Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.

Orringer D, Lau D, Khatri S, Zamora-Berridi GJ, Zhang K, Wu C, Chaudhary N, Sagher O.

J Neurosurg. 2012 Nov;117(5):851-9. doi: 10.3171/2012.8.JNS12234. Epub 2012 Sep 14.

PMID:
22978537
8.

Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.

Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, Clerici E, Rossi M, Scorsetti M, Bello L.

J Neurooncol. 2017 Oct;135(1):129-139. doi: 10.1007/s11060-017-2559-9. Epub 2017 Jul 8.

PMID:
28689368
9.

Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes.

Mampre D, Ehresman J, Pinilla-Monsalve G, Osorio MAG, Olivi A, Quinones-Hinojosa A, Chaichana KL.

Br J Neurosurg. 2018 Oct;32(5):528-535. doi: 10.1080/02688697.2018.1498450. Epub 2018 Aug 3.

PMID:
30073866
10.

The Survival Advantage of "Supratotal" Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique.

Esquenazi Y, Friedman E, Liu Z, Zhu JJ, Hsu S, Tandon N.

Neurosurgery. 2017 Aug 1;81(2):275-288. doi: 10.1093/neuros/nyw174. Erratum in: Neurosurgery. 2017 Aug 1;81(2):404. Neurosurgery. 2017 Dec 1;81(6):1047.

PMID:
28368547
11.

Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.

Woo PYM, Ho JMK, Tse TPK, Lam SW, Mak CHK, Chan DTM, Lee MWY, Wong ST, Chan KY, Poon WS.

J Clin Neurosci. 2019 May;63:134-141. doi: 10.1016/j.jocn.2019.01.022. Epub 2019 Jan 31.

PMID:
30712777
12.

Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study.

Roh TH, Kang SG, Moon JH, Sung KS, Park HH, Kim SH, Kim EH, Hong CK, Suh CO, Chang JH.

J Neurosurg. 2019 Mar 1:1-7. doi: 10.3171/2018.12.JNS182558. [Epub ahead of print]

PMID:
30835701
13.

Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.

Hollon T, Nguyen V, Smith BW, Lewis S, Junck L, Orringer DA.

J Neurosurg. 2016 Aug;125(2):410-8. doi: 10.3171/2015.7.JNS151187. Epub 2016 Jan 8. Review.

PMID:
26745489
14.

Impact of removed tumor volume and location on patient outcome in glioblastoma.

Awad AW, Karsy M, Sanai N, Spetzler R, Zhang Y, Xu Y, Mahan MA.

J Neurooncol. 2017 Oct;135(1):161-171. doi: 10.1007/s11060-017-2562-1. Epub 2017 Jul 6.

PMID:
28685405
15.

Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma.

Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N.

J Neurol Surg A Cent Eur Neurosurg. 2019 Jul;80(4):262-268. doi: 10.1055/s-0039-1685170. Epub 2019 Apr 9.

PMID:
30965373
16.

Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT.

J Neurosurg. 2012 Dec;117(6):1032-8. doi: 10.3171/2012.9.JNS12504. Epub 2012 Oct 5.

PMID:
23039151
17.

Counseling Patients with a Glioblastoma Amenable Only for Subtotal Resection: Results of a Multicenter Retrospective Assessment of Survival and Neurologic Outcome.

Coburger J, Segovia J, Ganslandt O, Ringel F, Wirtz CR, Renovanz M.

World Neurosurg. 2018 Jun;114:e1180-e1185. doi: 10.1016/j.wneu.2018.03.173. Epub 2018 Apr 3.

PMID:
29621607
18.

Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article.

Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, Skrap M.

J Neurosurg. 2012 Dec;117(6):1039-52. doi: 10.3171/2012.8.JNS12393. Epub 2012 Oct 5.

PMID:
23039150
19.

Which Parameter Is More Important for the Prognosis of New-Onset Adult Glioblastoma: Residual Tumor Volume or Extent of Resection?

Xing Y, Wang X.

World Neurosurg. 2018 Aug;116:e444-e451. doi: 10.1016/j.wneu.2018.05.003. Epub 2018 May 16.

PMID:
29753893
20.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389

Supplemental Content

Support Center